AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** An isolated antagonist of ~~the~~ a ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 8 to 10 N-terminal amino acids of native sauvagine and comprising the amino acid sequence Xaa_1-Xaa_2-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH_2, wherein Xaa_1 is a neutral amino acid, and Xaa_2 is a charged amino acid.

2. **(Currently Amended)** The isolated antagonist of claim 1 lacking the 10 N-terminal amino acids of native sauvagine.

3. **Canceled**

4. **(Currently Amended)** The isolated antagonist of claim ~~3~~1, wherein Xaa_1 is a hydrophobic amino acid, and Xaa_2 is Glu or His.

5. **(Currently Amended)** The isolated antagonist of claim 4, wherein Xaa_1 is Leu.

6. **(Currently Amended)** The isolated antagonist of claim ~~3~~1, wherein Xaa_1 is a polar amino acid, and Xaa_2 is Glu or His.

7. **(Currently Amended)** The isolated antagonist of claim 6, wherein Xaa_1 is Tyr.

8. **(Currently Amended)** The isolated antagonist of claim ~~3~~1, wherein Xaa_1 is in the D-configuration.

9. **(Currently Amended)** The isolated antagonist of claim 8, wherein Xaa_1 is D-Leu.

10. **(Currently Amended)** The isolated antagonist of claim 8, wherein Xaa_1 is D-Tyr.

11. **(Currently Amended)** The isolated antagonist of claim 5, wherein Xaa_2 is Glu.

12. **(Currently Amended)** The isolated antagonist of claim 8, wherein Xaa_1 is D-Phe.

13. **(Currently Amended)** The isolated antagonist of claim 7, wherein Xaa_2 is His.

14. **(Currently Amended)** An isolated antagonist of ~~the~~ a ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 11 N-terminal amino acid of native sauvagine, wherein the N-terminal amino ~~acid~~ acids of said antagonist is a charged amino acid and comprising the amino acid sequence Xaa_1-Xaa_2-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH_2, wherein Xaa_1 is a neutral amino acid, and Xaa_2 is a charged amino acid.

15. **(Currently Amended)** The isolated antagonist of claim 14, wherein said charged amino acid is positively charged.

16. **(Currently Amended)** The isolated antagonist of claim 15, wherein said charged amino acid is His.

17. **(Currently Amended)** The isolated antagonist of claim 14 which comprises a phenyldiazirine group coupled to the N-terminal amino acid of said antagonist.

18. **(Currently Amended)** The isolated antagonist of claim 17, wherein said phenyldiazirine group is a 4-(1-azi-2,2,2-trifluoroethyl)benzoyl (ATB)-group.

19. **Canceled**

20. **Canceled**

21. **Canceled**

22. **Canceled**

23. **Canceled**

24. **Canceled**

25. **Canceled**

26. **Canceled**

27. **(Currently Amended)** A pharmaceutical composition comprising the antagonist of claim 1, ~~the polynucleotide of claim 19, the vector of claim 20, the antibody of claim 25 and/or the anti-idiotypic antibody of claim 26~~ and ~~optionally~~ a pharmaceutically acceptable carrier and/or diluent.

28. **Canceled**

29. **(Currently Amended)** A kit comprising

~~(a)~~ an antagonist of claim 1~~;~~

~~(b) the polynucleotide of claim 19;~~

~~(c) the vector of claim 20;~~

~~(d) the antibody of claim 25; and/or~~

~~(e) the anti-idiotypic antibody of claim 26~~.

30. **Canceled**

31. **(Previously Presented)** The antagonist of claim 1, wherein said CRFR2 is CRFR2α or CRFR2β.

32. **Canceled**

33. **Canceled**